Dr. Kambhampati on Frontline Ibrutinib Plus Obinutuzumab in CLL
February 6th 2019
Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.